Kornimate/medical-research-clean huggingface dataset:
blood flow mri for monitoring brain tumors

Conditions: Brain Tumors

Summary: the investigators are studying the use of an advanced magnetic resonance imaging (mri) technique for measuring blood flow into brain tumors. this technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard mri scanner.

our goals are: 1. to compare the blood flow measured with this technique with measures of tumor blood vessel density in pieces of the tumor surgically removed as a normal part of clinical treatment. this will confirm a relationship between the imaging measurements and the microscopic characteristics of tumors. 2. to compare the blood flow in tumors before therapy with the concentration of choline, an indicator of cell proliferation. this choline concentration can be measured with another mri technique. this information will demonstrate the relationship between cell proliferation and blood supply and will also determine whether the choline measurement adds additional information that is clinically necessary. 3. to determine the reproducibility of blood flow measurements in tumors. this is necessary to better understand the sensitivity of the technique to changes in flow caused by a treatment or changes in tumor vascularity. 4. to monitor changes in blood flow after initial treatment. since sometimes tumors can reappear, the repeated measures will help determine how useful this new imaging technique is at detecting such recurring tumors.

Eligibility criteria:
inclusion criteria: * diagnosed with or are suspected of having a glioma exclusion criteria: * contraindications to mri which may include the following 1. pacemaker 2. mri incompatible metal implant 3. recently implanted vascular clip 4. history of claustrophobia 5. metal fragment within the eye subjects who have received nonstandard therapy may be excluded if the therapy might alter tumor blood flow or other imaging characteristic.
efficacy of suvorexant to treat insomnia related to bipolar disorder

Conditions: Insomnia; Bipolar Disorder

Summary: the purpose of this study is to evaluate the efficacy of suvorexant, added to existing medications, for treatment-resistant insomnia in individuals with bipolar disorder. the investigators hypothesize that participants receiving suvorexant for one week will experience significantly greater improvement in sleep duration compared to participants receiving placebo.

participants will be randomized to receive double-blind suvorexant or placebo for one week, after which all participants will receive open treatment with suvorexant for three months.

Eligibility criteria:
inclusion criteria: 1. adult outpatients meeting diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for bipolar i disorder (296.70), bipolar ii disorder (296.89), or bipolar disorder not otherwise specified (296.80), with concurrent insomnia related to bipolar disorder (307.42). 2. currently taking ≥ 1 prescription psychotropic medication (hypnotic agents, anxiolytics, atypical antipsychotics, mood stabilizers, and/or antidepressants) for management of bipolar disorder. 3. subjective total sleep time (stst) \< 6 hours on ≥ 1 night during the prior week. exclusion criteria: 1. current hypo/manic symptoms, as evidenced by the young mania rating scale (ymrs) total score ≥ 12. 2. current (past 6 months) alcohol or substance use disorder. 3. current psychosis. 4. patients who are actively suicidal or evaluated as being a high suicide risk. 5. women who are currently pregnant or breastfeeding. 6. clinically significant abnormalities on baseline laboratory tests (comprehensive metabolic panel, fasting lipid panel, complete blood count (cbc) with differential, thyroid stimulating hormone). 7. presence of any unstable and/or potentially confounding neurological and/or medical disorder.
comparison of crt-d and crt-dx systems (crt-next)

Conditions: Heart Failure; Cardiac Resynchronization Therapy

Summary: the principal objective is to test non-inferiority of the crt-dx system as compared to a conventional crt-d system, in terms of the combined endpoint of mortality, hospitalizations due cardiovascular causes, any complication leading to loss of lead functionality, in the subset of patients without evidence of sinus dysfunction on optimal therapy.

resting heart rate is strongly associated with incident worsening heart failure (hf) and mortality. current devices for cardiac resynchronization (crt-d) normally provide atrio-ventricular (av) sequential pacing modes during resynchronization, but the best pacing programming strategy is not clear. on the one hand a basic rate of 50 to 70 bpm (optionally with some rate-responsive function) could be considered for therapy up-titration, specifically betablockers; on the other hand, increasing pacing rates may partially reduce benefits from resynchronization, reducing filling time and contractility reservoir. the pegasus investigation is the only large randomized investigation comparing ddd with 70 bpm basic rate to ddd(r) @40 bpm. results showed no difference in investigation endpoints, including mortality and hf-hospitalization. these results may support the use of a device implementing both a crt function and a right ventricular single-lead with and an atrial sensing dipole (crt-dx system). this system can track ventricular pacing and resynchronization following atrial sensing, even if it cannot provide atrial pacing support. it should be assessed whether such limitation is counterbalanced by the advantages related to the reduced number of necessary leads, with simplified implantation and less complications. the objective of the investigation is to assess whether atrial pacing support is really necessary in the subset of patients with indication to crt-d and no evidence of sinus dysfunction on optimal therapy. the investigation will test the hypothesis that a crt-dx system is not inferior to a conventional crt-d system in this class of subjects.

Eligibility criteria:
inclusion criteria: 1. male and female patients ≥ 18 years old 2. patients willing to participate in the investigation and signing the patient informed consent (pic) form; 3. indication to crt-d implant according to current esc guidelines on cardiac pacing and cardiac resynchronization therapy 4. sinus rhythm at time of implant; 5. optimized medical therapy according to current esc guidelines 6. rest heart rate (hr) \>45 bpm at baseline ecg, with betablocker therapy at optimal medical dosage; or, if rest hr\ 85 bpm. exclusion criteria: 1. any indication to atrial pacing according to current guidelines; 2. both: resting heart rate \<45 bpm at baseline ecg, with betablocker therapy at optimal medical dosage and maximum heart rate at the 6-minute walking test \<85 bpm; 3. nyha class iv; 4. permanent atrial fibrillation 5. replacement of/upgrading from previously implanted pacing system; 6. dialysis patients; 7. pregnant or breast-feeding women.

Keywords: crt-d crt-dx atrial pacing
thrombo-inflammation biomarkers trial in acute cerebral hypoxia

Conditions: Cerebral Hypoxia; Ischemic Stroke

Summary: the goal of this trial is to study, in three well-defined clinical situations responsible for cerebral hypoxia, the concentrations of biomarkers of thrombo-inflammation compared to a population of patients without cerebral hypoxia, and to study in patients with cerebral hypoxia the association between these concentrations and the clinical evolution.


Eligibility criteria:
inclusion criteria: - for cases, admitted within the first 36 hours of an acute neurological symptom related to : * an ischaemic cerebrovascular accident (icva) eligible for a mechanical thrombectomy procedure, * a subarachnoid haemorrhage (sah, all aetiologies) : patient presenting with at least a modified fisher scale 3 or 4, * an intra-parenchymal haematoma (iph) with greatest axis ≥ 20mm or with nihss on admission \>4. or * for control patients, admitted within 7 days of the onset of acute neurological symptomatology related to a clinical diagnosis of transient ischaemic attack (tia) - based on thorough questioning of the patient on admission - and prior to imaging, with an abcd2≥ 2 score. * express consent to participate in the study. * member or beneficiary of a social security. exclusion criteria: * pre-existing functional and/or cognitive disability * patient under legal protection. * pregnant or breastfeeding woman. * patient with secondary haemorrhagic transformation. secondary exclusion criteria : * patients with an ischaemic lesion visible on imaging, unrelated to large vessel occlusion and therefore ineligible for mechanical thrombectomy. * patients diagnosed with an acute non-vascular neurological pathology (migraine, epilepsy, etc.). * tia patients presenting an abnormality on follow-up imaging 24-48 hours after the initial imaging. excluded patients will be replaced.
ultrasound-guided infraclavicular block with lidocaine or ropivacaine for closed reduction of distal radius fractures

Conditions: Distal Radius Fractures; Lidocaine; Ropivacaine; Fracture Dislocation; Closed Reduction of Fracture and Application of Plaster Cast; Colles' Fracture

Summary: to investigate the feasibility of the lateral infraclavicular plexus brachialis (lic) block for acute closed reduction of distal radius fractures, the investigators will compare the pain-relieving and muscle-relaxing properties of the lic block with short- and long-acting local anesthetics in different concentrations but at the same volume. in addition to motor and sensory blockade during repositioning, feasibility will also be assessed by other patient-related and block-related factors, as well as by factors related to the repositioning and plastering procedure.


Eligibility criteria:
inclusion criteria: patients who have given written informed consent to participate in the study after having understood it, as well as: • having a distal radius fracture requiring closed reduction exclusion criteria: patients who meet one or more of the following criteria will be excluded from participating in the study: * bmi \> 40 kg/m2 * weight \< 50 kg * age \< 18 years * american society of anesthesiologists (asa) physical status classification system grade \>3 * allergy to experimental drugs * patients who cannot cooperate with the examinations or treatment * patients who do not understand or speak danish * patients with peripheral or central neurological disease or nerve damage with neurological effect on the upper extremity, where closed reduction is required

Keywords: anesthetics, local regional anesthesia peripheral nerve block brachial plexus block lateral infraclavicular block closed reduction distal radius fracture colles' fracture wrist fracture
treatment with bempedoic acid and/or its fixed-dose combination with ezetimibe in routine clinical practice in patients with primary hypercholesterolemia or mixed dyslipidemia

Conditions: Primary Hypercholesterolemia; Mixed Dyslipidemia

Summary: cardiovascular disease (cvd), especially its management and associated costs, remains a major concern globally. there is a direct correlation between circulating levels of low-density lipoprotein cholesterol (ldl-c) and the incidence of cvd. this study will assess bempedoic acid/fdc in a real-world clinical setting in adult patients in spain with hypercholesterolaemia or mixed dyslipidemia.

this non-interventional study will be conducted in order to further understand the potential risks and benefits of bempedoic acid/fixed dose combination (fdc) with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia and to gain insight into the effectiveness (managing plasma levels of ldl-c) as well as safety (clinical events associated with the treatment modalities). no study medication will be provided as part of this protocol to the patients. medications will be as prescribed by the treating physician in line with clinical practice.

Eligibility criteria:
inclusion criteria: * written informed consent to participate * at least 18 years of age * participants suffering from documented primary hypercholesterolemia or mixed dyslipidemia * part 1: for participants treated to a maximum of 6 months or intended to be treated with bempedoic acid/fdc under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the participant in the study at the discretion of the physician under no reimbursement conditions at enrollment * part 2: for participants treated or intended to be treated with bempedoic acid/fdc under usual clinical practice conditions and as long as the decision of the physician to start treatment is prior to the inclusion of the patient in the study under reimbursed conditions at enrollment * no contraindications exist according to the smpc of bempedoic acid/ fdc * no concurrent participation in an interventional study (simultaneous participation in other non-interventional studies is possible) * life expectancy \> 1 -year exclusion criteria: * as this is a non-interventional study, no explicit exclusion criteria exist in order to avoid selection bias and to allow for documentation of routine clinical practice.

Keywords: primary hypercholesterolemia mixed dyslipidemia bempedoic acid and/or its fixed-dose combination with ezetimibe
effect of enhanced external counterpulsation

Conditions: Enhanced External Counterpulsation (EECP); Acute Myocardial Infarction (AMI); Drug-coated Balloon; Cardiac Rehabilitation

Summary: this study evaluated the efficacy and safety of enhanced extracorporeal counterpulsation for cardiac rehabilitation in patients after dcb for acute myocardial infarction.


Eligibility criteria:
inclusion criteria: * patients with ami diagnosed based on the universal definition of myocardial infarction criteria * a single vessel infarcted, and syntax score ≤22 * patients treated using dcb * patients without eecp contraindications * patients aged 18-75 years * patients who had signed informed consent and were able to cooperate in completing the study exclusion criteria: * patients with lower limb deep venous thrombosis and active thrombophlebitis * patients with moderate to severe valvular heart disease, especially those with aortic insufficiency and/or stenosis * patients with moderate to severe pulmonary arterial hypertension (mean pulmonary arterial pressure \>50 mmhg) * patients with aortic, cerebral or dissecting aneurysms * patients with uncontrolled hypertension (\>180/110 mmhg) * patients with decompensated heart failure (cardiac function of grade iv) * patients with arrhythmia that might interfere with the electrocardiographic gating function of the eecp device * patients with haemorrhagic diseases or obvious bleeding tendencies * patients with infected lesions in their limbs that may affect eecp * pregnant women * patients with ventricular aneurysm and mural thrombus detected through echocardiography
giant cell arteritis and differential diagnoses associated with positive temporal artery biopsy

Conditions: Giant Cell Arteritis; Vasculitis

Summary: temporal artery biopsy is a useful tool helping to the diagnosis of giant cell arteritis. however, other diagnoses might be associated with abnormal temporal artery biopsy. the purpose of this study is to describe the frequency of giant cell arteritis differential diagnoses with positive temporal artery biopsy.


Eligibility criteria:
inclusion criteria: * positive artery biopsy between january 1st 2000 and july 25th 2019 exclusion criteria: * orther vascular biopsy than temporal artery biospy

Keywords: giant cell arteritis temporal artery biopsy vasculitis
bananas as an energy source during exercise: a metabolomics approach

Conditions: Intense Exercise

Summary: this study compared the acute effect of ingesting bananas (ban) versus a 6% carbohydrate drink (cho) on 75-km cycling performance and post-exercise inflammation, oxidative stress, and innate immune function using traditional and metabolomics-based profiling.

trained cyclists (n=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting ban or cho (0.2 g/kg carbohydrate every 15 min). pre-, post-, and 1-h-post-exercise blood samples were analyzed for glucose, granulocyte (gr) and monocyte (mo) phagocytosis (phag) and oxidative burst activity, nine cytokines, f2-isoprostanes, ferric reducing ability of plasma (frap), and metabolic profiles using gas chromatography-mass spectrometry.

Eligibility criteria:
inclusion criteria: * male * ages 18-45 years * cyclists, road racing experience. * willing to avoid the use of supplements, herbs, medications during the study. exclusion criteria: * female * over the age of 45 years * no cycling racing experience * using supplements and medications during the study

Keywords: bananas exercise metabolomics oxidative stress inflammation immune function
clinical trial of hrs-4642 plus shr-a2102 in patients with advanced solid tumors

Conditions: Solid Tumors

Summary: the purpose of this study is to observe and evaluate the efficacy and safety of hrs-4642 combined with shr-a2102 in the treatment of advanced solid tumors

this study is a prospective, single-arm, exploratory clinical trial. it plans to enroll patients with advanced solid tumors , treating them with hrs-4642 in combination with shr-a2102. the entire study is divided into two stages: a safety run-in period and an efficacy exploration period.

Eligibility criteria:
inclusion criteria: 1. have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural requirements 2. the age of signing the informed consent is from 18 to 75 years old, regardless of gender 3. subjects with pathologically confirmed locally advanced unresectable or metastatic solid tumors 4. the ecog score is 0 or 1 5. expected survival ≥12 weeks 6. at least one measurable lesion according to recist v1.1 criteria 7. good level of organ function 8. male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods exclusion criteria: 1. subjects with uncontrolled or active brain metastasis； 2. subjects with clinical significant lung disease; 3. subjects with history of autoimmune diseases; 4. known active hepatitis b or c infection; 5. subjects with severe cardiovascular and cerebrovascular diseases 6. uncontrolled tumor-related pain 7. severe infections that require intravenous antibiotic, antiviral or antifungal control 8. clinically symptomatic moderate to severe ascites; uncontrollable or moderate or above pleural effusion, pericardial effusion 9. received anti-tumor therapy 4 weeks prior to initiation of study treatment. 10. known allergic to any compound of shr-a2102 or hrs-4642 11. other serious accompanying illnesses, which, in the investigator's assessment, could seriously adversely affect the safety of the treatment
the safety and efficacy of recombinant human prolactin

Conditions: Healthy

Summary: medications used to increase breast milk production increase prolactin secretion, the main hormone of lactation. there are no fda approved medications used to improve breast feeding, but metoclopramide is used off-label and can have intolerable side effects. we examined the biological activity and safety of recombinant human prolactin (r-hprl) as a potential medication to augment lactation. in this study, the effect of r-hprl on breast milk production in women who did not recently deliver a baby and its effect on the bones and menstrual cycle were tested.

there are no fda approved medications in the u.s. to augment lactation. metoclopramide is used off-label but can have intolerable side effects. we examined the biological activity and safety of recombinant human prolactin (r-hprl) as preliminary data for its use to augment lactation. healthy, non-postpartum women (n=21) with regular menstrual cycles underwent a 7 day randomized, double-blind, placebo-controlled trial of r-hprl. galactorrhea, markers of bone turnover, calcium homeostasis and gonadal function were measured and side effects recorded.

Eligibility criteria:
inclusion criteria: healthy subjects will meet the following criteria: 1. 18 to 40 years of age 2. normal weight (bmi 17 to £ 30 kg/m2) 3. good general health 4. on no medications for at least 3 months before the study 5. regular menstrual cycles every 25-35 days with ovulation documented by a luteal phase progesterone level 6. no evidence of androgen excess 7. normal tsh, prolactin and hematocrit 8. no current interest in conception 9. no history of osteoporosis 10. no use of medications known to affect bone turnover 11. no alcoholism 12. no smoking 13. no history of medical problems or treatment known to affect bone turnover. exclusion criteria: subjects will be excluded for pregnancy or evidence of breast masses.

Keywords: galactorrhea prolactin bone turnover menstrual cycle control groups women
multidimensional rehabilitation intervention in colorectal cancer survivors

Conditions: Colorectal Cancer Survivor; Rehabilitation; Quality of Life

Summary: a metaverse-based multidimensional rehabilitation program will be implemented for colorectal cancer survivors who have undergone curative surgery and adjuvant therapy. the intervention is based on the behavior change wheel and includes dietary intervention, exercise intervention, psychological support, and behavior management. through various methods such as training, education, and motivation, the program aims to enhance the patients' functional ability, opportunities, and motivation, thereby promoting healthy behavior. outcome measures include quality of life, fear of recurrence, and adoption of a healthy lifestyle. the intervention period is 4 weeks, with evaluations conducted at baseline and week 4 of the intervention


Eligibility criteria:
inclusion criteria: * patients undergoing adjuvant therapy after curative surgery for colorectal cancer.; * age 18 years old and under 65 years old, estimated survival period ≥ 6 months; * pg-sga (patient-generated subjective global assessment) score less than 4. * be able to walk without assistance; * conscious and intellectually normal; * voluntarily participate in the research of this topic and provide the consent form for medical record review; * mobile phones can be used. exclusion criteria: * patients with multiple cancers. * tumors not completely resected. * patients with severe psychological disorders, severe visual or hearing impairments, or other conditions that hinder intervention. * patients with severe complications such as short bowel syndrome, crohn's disease, ulcerative colitis, diverticulitis, previous stroke, congestive heart failure or edema, liver or kidney failure, or other conditions that affect patient compliance. * in addition to colorectal cancer or any other diseases deemed unsuitable for participation by the researchers, patients with severe heart, liver, lung, or kidney diseases. * patients with special dietary requirements.

Keywords: colorectal cancer survivor rehabilitation quality of life fear of cancer recurrence lifestyle home-based